Press

November 18, 2024

Convergent Therapeutics Announces First Shipments of Actinium 225 from Cardinal Health to Support the CONVERGE-01 Phase 2 Clinical Trial

September 24, 2024

Convergent Therapeutics Announces First Patient Treated in Phase II Clinical Trial with Lead Therapeutic Candidate and Corporate Updates

April 3, 2024

Convergent Therapeutics Announces FDA Clearance of IND Application for CONV01-α, a Best-in-Class Radioantibody Targeting Prostate-Specific Membrane Antigen

March 4, 2024

Convergent Therapeutics Appoints Scott Myers as Chairman of its Board of Directors

September 6, 2023

Convergent Therapeutics Expands Leadership Team with the Appointments of Neil Bander, MD. as Chief Scientific Officer, Eric M. Sullivan as Chief Financial Officer, and Dimitris Voliotis, MD. as Senior Vice President of Clinical Development

May 25, 2023

Convergent Therapeutics to Announce Clinical Trial Updates on its Lead Candidate at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023

May 3, 2023

Convergent Therapeutics Announces $90 Million Series A Financing to Advance the Clinical Development of Radiopharmaceuticals for the Treatment of Prostate Cancer and Other Solid Tumors

April 17, 2023

Convergent Therapeutics Announces Updates on its Lead Therapeutic Candidate at the American Association for Cancer Research (AACR) Annual Meeting 2023

March 20, 2023

Convergent Therapeutics to Announce Clinical Trial Updates on its Lead Candidate at the American Association for Cancer Research (AACR) Annual Meeting 2023

February 16, 2023

Convergent Therapeutics Announces Presentations at the 2023 ASCO Genitourinary (GU) Cancers Symposium on its Lead Candidate

May 25, 2022

Convergent Therapeutics and IONETIX Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)

March 9, 2022

NorthStar Medical Radioisotopes and Convergent Therapeutics Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)

September 14, 2021

Convergent Therapeutics and Point Biopharma Announce a Collaboration to Evaluate CONV01-α (Rosopatamab-²²⁵Ac) in combination with PNT2002 for Progressive Metastatic Castration-Resistant Prostate Cancer

August 30, 2021

Convergent Therapeutics Appoints Alexander Brown as Chief Operating Officer

July 13, 2021

Convergent Therapeutics Appoints Philip Kantoff, M.D. as Chief Executive Officer

Convergent Therapeutics, Inc. is a biotechnology company focused on developing next-generation targeted radiotherapies to treat cancer.

Company

Connect

Contact

[email protected]